Showing results (511-520 of 1,063) with videos related to
Sort By:
Pageof 107
Alzheimer'S & Dementia (New York, N. Y.)|June 26, 2026
Person-centered intervention response in primary progressive aphasia: A secondary analysis of the Communication Bridge-2 randomized clinical trialEmily Rogalski, Ollie Fegter, Angela C Roberts, et al.Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's diseaseDrew R DeBay, George A Reid, Ian R Pottie, et al.Alzheimer'S & Dementia (New York, N. Y.)|June 22, 2026
Aβ- and tau-associated neuroinflammatory signatures in Alzheimer's diseaseBruna Bellaver, Guilherme Povala, Marco Antônio De Bastiani, et al.Alzheimer'S & Dementia (New York, N. Y.)|April 5, 2021
NEURoaid II (MLC901) in cognitively Impaired not demenTEd patientS (NEURITES): A pilot double blind, placebo-controlled randomized trialChristopher L H Chen, Trọng Hung Nguyen, Simeon Marasigan, et al.Alzheimer'S & Dementia (New York, N. Y.)|July 14, 2026
Heterogeneous responses to memantine in Alzheimer's disease: A precision medicine approach using iPSC modelsCristina Zivko, Ram Sagar, Waqar Ahmed, et al.Alzheimer'S & Dementia (New York, N. Y.)|July 9, 2026
Identifying populations with faster cognitive decline using blood-based biomarkersJames Russell Pike, Yongmei Liu, Theresa Chisolm, et al.Alzheimer'S & Dementia (New York, N. Y.)|May 4, 2026
Population pharmacokinetics of remlifanserin (ACP-204), a serotonin 2A receptor inverse agonistMona Darwish, Nancy Lin, Bryan Dirks, et al.Alzheimer'S & Dementia (New York, N. Y.)|April 27, 2026
Druggable genome-wide Mendelian randomization analysis identifies potential treatment targets in vascular dementiaMatthew J Lennon, Ying Xu, Anbupalam Thalamuthu, et al.Alzheimer'S & Dementia (New York, N. Y.)|April 27, 2026
Spiritual practices for dementia care of Black persons: An integrative reviewPeace Esther Johnson, Roxanne VandermauseAlzheimer'S & Dementia (New York, N. Y.)|April 13, 2026
The I-Learn Cognition and Behavior program for non-pharmacological treatment of agitation in nursing home residents with neurocognitive disorders: A cluster randomized trialCéline Lourdel, Alix Launay, Alexia Couteau, et al.Pageof 107